Trial Profile

A non-interventional, multicentric, prospective study to evaluate the safety and efficacy of Ixazomib in combination with lenalidomide and dexamethasone in real life

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Dec 2022 Final results (N=376) presented at the 64th American Society of Hematology Annual Meeting and Exposition.
14 Dec 2021 Results of pooled analysis from INSIGHT MM, UVEA-IXA and REMIX; assessing the effectiveness of IRd in the overall RRMM, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
08 Dec 2020 Interim results (n=198) assessing IRD effectiveness and tolerance in the compassionate use program patient median study follow-up at 17.4 months, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com